You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 3
  • 917 Phase 1b trial of first-line bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, plus chemotherapy with or without bevacizumab in cervical cancer

Article info

Article menu

Download PDFPDF

Cervical cancer
917 Phase 1b trial of first-line bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, plus chemotherapy with or without bevacizumab in cervical cancer
Free

Authors

Citation

Oaknin A, Gil-Martin M, Diver E, et al
917 Phase 1b trial of first-line bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, plus chemotherapy with or without bevacizumab in cervical cancer
International Journal of Gynecologic Cancer 2021;31:A51-A52.

Publication history

  • First published October 12, 2021.
Online issue publication 
October 12, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.